SCHEMBL716476

SCHEMBL716476

CC(NC(=O)O)c1cc2cccc(Cl)c2nc1N1CCN(S(C)(=O)=O)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.40
CNR2 P34972 2/20 0.40
RAB9A P51151 2/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 4/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KDM4E B2RXH2 4/20 0.37
HSD17B10 Q99714 2/20 0.37
HPGD P15428 2/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
NPY5R Q15761 1/20 0.37
POLB P06746 3/20 0.37
MAPK1 P28482 2/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716164 0.88 AKT1 (0.40) CNR2CYP2C9TSHRCASP1CASP7
SCHEMBL17530817 0.86 CNR1 (0.37) CNR1CNR2RAB9ALMNAALDH1A1
SCHEMBL715607 0.86 CNR2 (0.43) CNR1CNR2ALDH1A1KDM4ENPY5R
SCHEMBL715577 0.85 CNR1 (0.44) CNR1CNR2SMO
SCHEMBL717045 0.85 PIK3CB (0.40) ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL713901 0.84 AKT1 (0.43) CNR1CNR2ALDH1A1CYP2C9KDM4E
SCHEMBL716682 0.83 MAPT (0.48) CNR1CNR2LMNAALDH1A1KDM4E
SCHEMBL714963 0.83 ALDH1A1 (0.41) CNR1CNR2RAB9ALMNAALDH1A1
SCHEMBL17530846 0.83 ALDH1A1 (0.41) CNR1CNR2RAB9ALMNAALDH1A1
SCHEMBL15875804 0.82 PIK3CA (0.39) CNR1CNR2ALDH1A1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 CNR1 2238/4885CNR2 1488/4885RAB9A 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.